Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS neoantigen nanovaccine-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Subcutaneous, Intralymphatic
01
Overview
The KRAS neoantigen nanovaccine developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is an immunotherapy candidate designed for the adjuvant treatment of KRAS-mutated colorectal and pancreatic cancers. The vaccine is constructed using a proprietary platform (FOLactis) that utilizes the bacterial membranes of an engineered *Lactococcus lactis* strain to deliver KRAS neoantigenic peptides. By leveraging the natural immunogenicity of bacterial membranes as an adjuvant, the nanovaccine aims to stimulate a robust T-cell response against tumor cells harboring KRAS mutations, thereby reducing the risk of recurrence in post-operative patients. It is currently being evaluated in Phase I/II clinical trials via subcutaneous or intralymph node administration.
- Other names
- KRAS Neoantigen Nanovaccine
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on KRAS neoantigen nanovaccine-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS neoantigen nanovaccine-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.